Cefditoren
- Atc Codes:J01DD16
- CAS Codes:104145-95-1#117467-28-4
- PHARMGKB ID:104145-95-1#117467-28-4
Table of contents
- Brand Names
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Drug Interactions
- Nutrition/Nutraceutical Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
Europe
Greece: Spectracef; Italy: Giasion; Portugal: Meiact, Spectracef; Spain: Meiact, Spectracef, Telo.
North America
USA: Spectracef.
Latin America
Mexico: Spectracef.
Asia
Japan: Cefditoren, Meiact MS.
Drug combinations
Chemistry
Cefditoren: C~19~H~18~N~6~O~5~S~3~. Mw: 506.58. (+)-(6R,7R)-7-[2-(2-Amino-4-thiazolyl)glyoxylamido]-3-[(Z)-2-(4-methyl-5-thiazolyl)vinyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7^2^-(Z)-(O-methyloxime). CAS-104145-95-1; CAS-117467-28-4 (pivoxil).
Pharmacologic Category
Antibacterials; Third Generation Cephalosporins. (ATC-Code: J01DD16).
Mechanism of action
Inhibits bacterial cell wall synthesis by binding to one or more of the penicillin-binding proteins. Usually bactericidal. Cefditoren pivoxil is a prodrug and has little, if any, antibacterial activity until hydrolyzed in vivo to cefditoren. It is active in vitro and in clinical infections against Gram-positive aerobic bacteria, such as Staphylococcus aureus (oxacillin-susceptible strains, including β-lactamase-producing strains), Streptococcus pneumoniae (penicillin-susceptible strains only), and Streptococcus pyogenes (group A β-hemolytic streptococci). Also active in vitro against Streptococcus agalactiae (group B streptococci), groups C and G streptococci, and viridans streptococci (penicillin-susceptible and intermediate strains). Oxacillin-resistant S. aureus (methicillin-resistant S. aureus) are resistant. Active in vitro and in clinical infections against Gram-negative aerobic bacteria such as Haemophilus influenzae (including β-lactamase-producing strains), H. parainfluenzae (including β-lactamase-producing strains), and Moraxella catarrhalis (including β-lactamase-producing strains). Inactive against fungi and viruses.
Therapeutic use
Acute bacterial exacerbation of chronic bronchitis, community-acquired pneumonia, pharyngitis or tonsillitis, uncomplicated skin and skin-structure infections due to susceptible organisms.
Pregnancy and lactiation implications
Adverse events not observed in animal reproduction studies. Other cephalosporins cross the placenta and are considered safe in pregnancy.
Unlabeled use
Contraindications
Hypersensitivity to cefditoren, any component of the formulation, other cephalosporins, or milk protein. Carnitine deficiency.
Warnings and precautions
May be associated with increased INR, especially in nutritionally-deficient patients, prolonged treatment, hepatic or renal disease. Use with caution in history of penicillin allergy (mainly if IgE-mediated reactions). Prolonged use may result in fungal or bacterial superinfection, including C. difficile-associated diarrhea and pseudomembranous colitis. Do not use in carnitine deficiency (causes renal excretion of carnitine; higher risk in long-term therapy). Caution in hepatic or renal impairment. Caution in history of seizure disorder (high levels may increase risk of seizures). Tablets contain sodium caseinate (risk of hypersensitivity reactions in milk protein hypersensitivity). May induce a positive direct Coombs’ test.